` UTHR (United Therapeutics Corp) vs S&P 500 Comparison - Alpha Spread

UTHR
vs
S&P 500

Over the past 12 months, UTHR has underperformed S&P 500, delivering a return of 11% compared to the S&P 500's 12% growth.

Stocks Performance
UTHR vs S&P 500

Loading

Performance Gap
UTHR vs S&P 500

Loading
UTHR
S&P 500
Difference

Performance By Year
UTHR vs S&P 500

Loading
UTHR
S&P 500
Add Stock

Competitors Performance
United Therapeutics Corp vs Peers

S&P 500
UTHR
ABBV
AMGN
GILD
VRTX
Add Stock

United Therapeutics Corp
Glance View

Economic Moat
Narrow
Market Cap
13.8B USD
Industry
Biotechnology

In the landscape of biotechnology, United Therapeutics Corp. has crafted a compelling narrative centered around innovation and transformation, principally targeting life-threatening conditions. Founded in 1996 by Martine Rothblatt, the company's inception was motivated by the urgent need to find solutions for her daughter's rare disease, pulmonary arterial hypertension (PAH). Over the years, United Therapeutics has stayed true to its pioneering ethos, focusing on creating and commercializing unique therapies that address the needs of patients with severe and often unmet health challenges. The core of its operations revolves around developing drugs that enhance survival and quality of life for individuals afflicted by PAH and other similar illnesses. Such dedication to research and pharmaceutical development has fostered a robust product pipeline, including therapeutics like Remodulin and Tyvaso, which play pivotal roles in the company's revenue generation. Financially, United Therapeutics sustains its momentum through a blend of strong patent portfolios and strategic market positioning, ensuring both competitive advantage and an ongoing revenue stream. By maintaining a keen focus on specific niches within the biotechnology sector, the company minimizes competition while maximizing the impact of its therapeutic solutions. Its business model thrives on the supply of specialized medications, which, given their critical nature, command premium pricing. Yet, United Therapeutics doesn’t solely pivot around drug sales; it is deeply invested in the future of medicine, notably venturing into areas like organ manufacturing and xenotransplantation, where it seeks to address broader and more complex health challenges. Through a blend of innovation, strategic partnerships, and diversification into emerging medical fields, United Therapeutics continues to cement its reputation as a leader in biotechnological advancement.

UTHR Intrinsic Value
274.53 USD
Overvaluation 10%
Intrinsic Value
Price
Back to Top